A nurse practitioner, physician assistant or physician can start a medical weight loss telemedicine clinic built around GLP-1 therapy in about 12 weeks, and the 2026 version looks different from the one that boomed in 2023 and 2024. The gating items are a licensure and practice-authority plan for every state you serve, a medication-sourcing strategy built on FDA-approved products (with compounding reserved for documented, patient-specific need), a screening and monitoring protocol you can defend, and marketing that never implies a compounded drug is approved, generic or equivalent to a branded one. This is a planning summary, not legal or medical advice; the rules changed several times in 18 months, so confirm every point with your state boards, counsel and the current FDA position before you see a patient.
Why medical weight loss works as a cash-pay telemedicine model
Three things make this specialty a natural fit for a remote, cash-pay practice. Demand is broad and already educated: obesity affects roughly four in ten American adults by public health estimates, and GLP-1 medications are household names, so patients arrive asking for a specific category of care. Coverage is uneven; many commercial plans exclude weight-management indications and Medicare generally has not covered these drugs for weight loss alone, so patients already expect to pay out of pocket. And the care is recurring by design: dose escalation happens over months, maintenance continues after that, and the visits are short, data-driven and video-friendly, with weight, blood pressure, side effects and adherence reviewed remotely from a home scale and a cuff.
What changed in 2026 is where the money sits. While compounded semaglutide and tirzepatide could be produced at scale during the FDA shortage, many clinics priced the program as “medication included” and lived on drug margin. With the shortages resolved and manufacturer direct-pay programs selling approved products at cash prices in the low hundreds per month, the durable clinic charges for clinical judgment, titration, monitoring, side-effect management and the nutrition and behavioral program around the drug. That is a better business, and a safer one.
Clinical scope and protocols at a high level
A medical weight loss clinic typically treats adults who meet the criteria in the approved labeling for anti-obesity medications (commonly a BMI of 30 or more, or 27 or more with a weight-related condition), with the clinician deciding for each patient. Many practices pair it with hormone or longevity care because the patients overlap. The protocols below are educational, not prescriptive.
Screening labs. A typical baseline is a comprehensive metabolic panel, lipid panel, HbA1c or fasting glucose, TSH and CBC, with lipase, a pregnancy test and other markers at the clinician’s discretion. Contraindications and cautions come from current labeling and clinical judgment; every intake form should screen for a personal or family history of medullary thyroid carcinoma or MEN 2 (the boxed warning on semaglutide and tirzepatide), pancreatitis history, pregnancy, breastfeeding or plans to conceive, type 1 diabetes or insulin use, significant GI disease such as gastroparesis, eating-disorder history, and mood or suicidality where labeling calls for it. Read the labeling for every product you prescribe, including the oral agents approved in late 2025 and 2026.
Titration and monitoring. Dose escalation is protocol-driven and clinician-determined, following the stepwise schedules in the labeling, typically in four-week increments, and slowed when GI effects warrant it. A common cadence is a check-in two to four weeks after initiation and after each dose step, monthly visits through titration, then every one to three months in maintenance, with repeat labs at three to six months or as indicated. Each visit reviews weight, blood pressure, GI symptoms, hydration, protein intake and resistance training, because preserving lean mass is part of the standard of care.
Nutrition and behavioral components. The medication is one component of a program. Clinics that retain patients build in protein targets, strength-training guidance, sleep and alcohol counseling, coaching or dietitian referral, and an honest conversation about maintenance and discontinuation, since weight regain after stopping therapy is well documented. Training. Obesity-medicine continuing education is expected; physicians can pursue board certification in obesity medicine, and NP and PA obesity-medicine courses are widely available. Document that you took them.
Regulatory and compliance: the 2026 GLP-1 picture
The shortage is over and “essentially a copy” rules are back
FDA declared the tirzepatide shortage resolved in December 2024 and the semaglutide shortage in February 2025, with wind-down periods for 503A pharmacies and 503B outsourcing facilities that ended in spring 2025; court challenges by the compounding industry did not win injunctions, as publicly reported. Off the shortage list, a 503A pharmacy may not compound an essentially-a-copy product regularly or in inordinate amounts, and a 503B facility may not compound from bulk substance unless the substance is on the 503B bulks list. In April 2026 FDA proposed excluding semaglutide, tirzepatide and liraglutide from that list, finding no clinical need; the comment period closed in mid-2026 and a final decision was pending as this guide was written. Confirm the current status.
What is still permitted
Patient-specific 503A compounding remains lawful where the prescriber determines and documents that a change from the approved product produces a significant clinical difference for that individual patient, such as a different strength, dosage form or an excipient allergy. FDA’s April 1, 2026 statement warned that formulaic “clinical difference” language does not meet the standard and named semaglutide combined with vitamin B12 as a product it may treat as essentially a copy depending on route and strength. The 2018 policy under which FDA does not act when a pharmacy fills four or fewer such prescriptions a month is a pharmacy-level allowance, not a business model. The practical conclusion: build on FDA-approved products and treat compounding as the documented exception, not the default.
Advertising enforcement is active
FDA has issued several waves of warning letters to telehealth companies over compounded GLP-1 marketing: a large wave in September 2025, about 30 letters in March 2026 and about 25 more in June 2026, as reported. The recurring findings are claims that a compounded product is the same as, a generic of, or as safe and effective as an approved drug; clinic-branded vials that obscure the source; efficacy figures borrowed from branded trials; and failure to say plainly that compounded drugs are not FDA-approved. States are moving too: California considered a 2026 bill requiring truthful promotion of compounded drugs, Indiana advanced a bill giving its pharmacy board enforcement authority over compounders, and at least one state pharmacy board has reported summary suspensions of weight-loss clinics and medical spas, all as reported. The rule for your website: no compounded-drug efficacy or safety claims, no sameness claims, clear disclosure of approval status.
Branded direct-pay programs
Manufacturer self-pay channels now set the price floor patients compare you to. As reported in 2026 and subject to change, LillyDirect lists Zepbound vials at roughly $299 to $449 a month by dose with refill-timing conditions; NovoCare lists Wegovy injection at around $349 a month with introductory pricing, and the Wegovy oral tablet, approved in December 2025, from roughly $149 to $299 by dose; orforglipron (Foundayo), approved in April 2026, has reported cash pricing of about $149 to $349 by dose. Confirm current figures on the manufacturer sites. Your clinic prescribes, the patient pays the manufacturer or pharmacy directly, and your fee covers care, which keeps you out of the drug-margin and sameness-claim problems.
Controlled substances, telehealth and state rules
GLP-1 receptor agonists are not controlled substances, so a clinic built on them needs no DEA registration for those prescriptions. Phentermine is Schedule IV; if you include it you need DEA registration, any state controlled-substance registration, PDMP checks and compliance with federal telemedicine prescribing rules, extended through December 31, 2026 while a permanent special-registration rule is finalized. Many weight-loss clinics simply exclude it. The usual telehealth layer still applies: you practice where the patient is located, so you need a license and the right practice authority in each state; corporate-practice-of-medicine rules decide who owns the clinical entity; most states require documented telehealth informed consent; and any pharmacy shipping into a state needs that state’s nonresident license. The Texas telemedicine practice guide shows how one state’s rules stack up. Your medication consent should cover approval status (if anything compounded is used), the boxed warning, GI effects, gallbladder and pancreatitis risk, pregnancy, lean-mass loss and the likelihood of regain after stopping.
See the full 12-week program →
Operations: EHR, labs, pharmacy, shipping and intake
The operating stack is lean: an EHR configured for cash-pay telehealth with e-prescribing to retail and manufacturer channels, a structured intake questionnaire with identity verification and weight history, and a messaging layer for side-effect questions between visits. Lab ordering runs through a Quest or Labcorp account with draw sites mapped to your patients, or through direct-to-consumer panels where state rules and lab policy allow. For branded products the pharmacy workflow is a retail or manufacturer-direct prescription; for the documented exception you keep one or two vetted 503A compounding pharmacies, checked for licensure in each state you serve, sterile-compounding credentials, certificates of analysis and cold-chain shipping, with the clinical-difference documentation in the chart, not a template. Patients supply a home scale and a blood-pressure cuff; the visit cadence drives the refill cadence, never the reverse.
Economics of a monthly GLP-1 program
Pricing varies widely by market and model; the ranges below are typical and should be treated as planning inputs, not promises. The fuller framework is in the telemedicine clinic pricing and revenue guide.
| Item | Typical cash-pay range (confirm for your market) |
|---|---|
| Initial consultation and screening | $99–$249 |
| Baseline labs (pass-through or bundled) | $75–$250 |
| Monthly management, medication paid directly to manufacturer or pharmacy | $75–$199 per month |
| Monthly program including a lawfully sourced medication | $299–$599 per month |
| Typical patient lifetime | 6–18 months, longer with a maintenance offer |
On a management-only model at roughly $150 a month, 10 active patients can mean about $1,500 in recurring monthly revenue, 25 patients about $3,750 and 50 patients about $7,500, before labs, add-on services or a maintenance tier. Those numbers assume retention, which is why the nutrition and behavioral program matters as much as the prescription. Bundling medication shows a higher top line, but the margin is thinner, the compliance exposure is higher and manufacturer programs now cap what patients will pay for the drug.
Patient acquisition for a weight loss clinic
Search intent here is strong and specific: “GLP-1 prescription online,” “semaglutide near me,” “medical weight loss” plus a city. National platforms dominate the generic phrases, so a small clinic wins on locality, clinician identity and depth: a Google Business Profile where you have an eligible address, honest pages on side effects, maintenance, cost and coverage, and short videos from the prescribing clinician. Referral channels are unusually good: gyms and trainers, dietitians, OB/GYN and primary-care practices that do not want to manage titration, and employers. Every piece of marketing must survive the FDA and FTC lens: no “lose X pounds” promises, no fabricated before-and-after results, no claims about compounded products, substantiated statements only, and testimonials that reflect typical results with clear disclosures. Treat the telemedicine clinic compliance guide as the baseline and add the GLP-1 advertising rules on top.
The 12-week Clinic In A Box map for a GLP-1 clinic
Clinic In A Box™ is a private, 1-on-1, done-with-you 12-week build led by an operator-mentor who runs active telemedicine clinics in the US, Colombia and Australia. Applied to medical weight loss, the weeks land like this.
- Weeks 1–4, Foundation. Niche and patient avatar; ownership and entity settled with counsel; licensure and practice-authority map for the first states; medication-sourcing policy written (approved products first, compounding only by documented exception, phentermine in or out); obesity-medicine CE scheduled; HIPAA framework, BAAs and an EHR configured for cash-pay telehealth.
- Weeks 5–8, Operations. Intake with contraindication gates; telehealth and medication consents; the titration and monitoring protocol in the EHR; lab account and draw sites or DTC panels; manufacturer-direct and retail prescribing workflows plus one vetted 503A pharmacy for exceptions; nutrition and coaching program; pricing tiers, maintenance offer and payment processing live.
- Weeks 9–12, Launch. Compliant website and Google Business Profile; referral outreach; soft launch and first patients titrated; retention and side-effect tracking; a 90-day roadmap with a standing review of FDA compounding and advertising updates.
By week 12 the practice has a compliant entity, a defensible sourcing policy, a configured EHR, lab and pharmacy relationships, a priced program and its first patients. Nurse practitioners should start with the nurse practitioner practice startup program page; physicians should read the physician telemedicine practice launch program page. The investment is $10,000 for two hours a week of direct work plus messaging between sessions; the full curriculum is on the Clinic In A Box™ program page.
Who this clinic is for, and who it is not for
It fits if you are a licensed NP, PA or physician who wants to own a weight-management service line, already see this demand in your patients, will run the program as care rather than a drug subscription, and can commit two hours a week for twelve weeks plus implementation time. It also fits an existing hormone or primary-care practice adding weight loss as a second line.
It does not fit if you want to resell compounded GLP-1s at volume, expect a fixed income figure to be promised, are not yet licensed or are under board action, or want someone else to run the clinic after launch. The regulatory direction in 2026 is toward approved products and documented care; a clinic designed against that direction is a liability.
Frequently asked questions
Can I still prescribe compounded semaglutide or tirzepatide in 2026?
Only in narrow, patient-specific circumstances. With both drugs off the FDA shortage list, a 503A pharmacy may compound a version only where the prescriber documents a significant clinical difference for that individual patient, and FDA has said formulaic documentation does not qualify. 503B bulk compounding is largely foreclosed, with a proposal to exclude these drugs from the bulks list pending final action. Confirm the current FDA position with counsel.
Do I need a DEA registration to run a GLP-1 weight loss clinic?
Not for GLP-1 medications, which are not controlled substances. You need one if you prescribe phentermine or any other scheduled drug, along with any state controlled-substance registration, PDMP compliance and the federal telemedicine prescribing rules in force at the time. Many clinics exclude phentermine for that reason.
What labs and monitoring does a GLP-1 program typically include?
A typical baseline is a comprehensive metabolic panel, lipid panel, HbA1c or fasting glucose, TSH and CBC, followed by check-ins after initiation and each dose step, monthly visits through titration, visits every one to three months in maintenance and repeat labs at three to six months or as indicated. The cadence is protocol-driven and clinician-determined.
How do patients get the medication if my clinic does not stock it?
You prescribe; the patient fills through a retail pharmacy, a manufacturer direct-pay program such as the reported LillyDirect or NovoCare channels, or insurance where covered. The clinic charges for consultation, monitoring and the program, which keeps it out of drug inventory, cold-chain shipping and the marketing claims that have drawn FDA warning letters.
Request your free info session
The next step is a free 30-minute info session covering your credential, your states, whether weight loss stands alone or pairs with another service line, your timeline and whether this is the right vehicle. Either way you leave with a clearer picture of what to do next. Call 844-734-2112 or use the form below.